Research Paper

Modeling the economic value of a Chagas’ disease therapeutic vaccine

Volume 8, Issue 9   September 2012
Pages 1293 - 1301
http://dx.doi.org/10.4161/hv.20966
Keywords: Trypanosoma cruzi, Chagas’ disease, Chagas’ therapeutic vaccine, Mexico, cost-effectiveness
Authors: Bruce Y. Lee, Kristina M. Bacon, Angela R. Wateska, Maria Elena Bottazzi, Eric Dumonteil and Peter J. Hotez

View affiliations

Abstract:
The health burden of Chagas’ disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2–6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas’ therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopathy.

Received: March 6, 2012; Accepted: June 1, 2012; Published Online: August 16, 2012

Preview:



Full Text - Ahead of Print Available - Log in!  

Advertisements